MRI Outperforms [18F]AV ‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Conclusions: [18F]AV ‐1451 tau‐PET measures increase over time in subjects with PSP, but longitudinal [18F]AV ‐1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials. © 2018 International Parkinson and Movement Disorder Society
Source: Movement Disorders - Category: Neurology Authors: Jennifer L. Whitwell,
Nirubol Tosakulwong,
Christopher G. Schwarz,
Hugo Botha,
Matthew L. Senjem,
Anthony J. Spychalla,
J. Eric Ahlskog,
David S. Knopman,
Ronald C. Petersen,
Clifford R. Jack,
Val J. Lowe,
Keith A. Josephs Tags: Research Article Source Type: research
More News: Brain | Cerebellum | Clinical Trials | Neurology | Parkinson's Disease | PET Scan | Progressive Supranuclear Palsy